Chiome Bioscience Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Public

  • Employees
  • 65

Employees

  • Stock Symbol
  • 4583

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $0.48
  • (As of Friday Closing)

Chiome Bioscience General Information

Description

Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Sumitomo Fudosan Nishi-Shinjuku Building 6
  • 3-12-1 Honmachi, Shibuya-ku
  • Tokyo, 151-0071
  • Japan
+81
Primary Industry
Drug Discovery
Stock Exchange
TKS
Vertical(s)
TMT
Corporate Office
  • Sumitomo Fudosan Nishi-Shinjuku Building 6
  • 3-12-1 Honmachi, Shibuya-ku
  • Tokyo, 151-0071
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Chiome Bioscience Stock Performance

As of 13-Nov-2026, Chiome Bioscience’s stock price is $0.48. Its current market cap is $39.1M with 81.1M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.48 $0.48 $0.40 - $0.81 $39.1M 81.1M 1.61M -$0.08

Chiome Bioscience Financials Summary

As of 30-Jun-2026, Chiome Bioscience has a trailing 12-month revenue of $3.98M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 28,919 40,721 99,190 41,838
Revenue 3,984 3,964 5,156 4,857
EBITDA (6,515) (6,694) (8,624)
Net Income (5,995) (6,566) (6,740) (8,683)
Total Assets 11,777 11,044 15,722 12,419
Total Debt 417 1,673 1,793 2,063
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Chiome Bioscience Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Chiome Bioscience‘s full profile, request access.

Request a free trial

Chiome Bioscience Patents

Chiome Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025248815-A1 Antibody or fragment thereof, and anti-influenza vaccine Pending 27-May-2024
AU-2023410319-A1 Anti-human cx3cr1 antibody Pending 22-Dec-2022
EP-4640709-A1 Anti-human cx3cr1 antibody Pending 22-Dec-2022
WO-2024135794-A1 Anti-human cx3cr1 antibody Inactive 22-Dec-2022
AU-2023300945-A1 Fusion protein Pending 30-Jun-2022 C07K16/2809
To view Chiome Bioscience’s complete patent history, request access »

Chiome Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Chiome Bioscience Investments & Acquisitions (6)

Chiome Bioscience’s most recent deal was a Joint Venture with Alfenax Biologics. The deal was made on 01-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Alfenax Biologics 01-Dec-2025 Joint Venture Drug Discovery
Biotechnol 01-Dec-2018 Merger/Acquisition Biotechnology
Trans Chromosomics 10-Feb-2017 Corporate Discovery Tools (Healthcare)
EVEC 30-Mar-2016 Later Stage VC Biotechnology
LivTech 13-Mar-2015 Secondary Transaction - Private Drug Discovery
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

Chiome Bioscience ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Laboratory Equipment and Services

Subindustry

Rank

Percentile

To view Chiome Bioscience’s complete esg history, request access »

Chiome Bioscience FAQs

  • When was Chiome Bioscience founded?

    Chiome Bioscience was founded in 2005.

  • Where is Chiome Bioscience headquartered?

    Chiome Bioscience is headquartered in Tokyo, Japan.

  • What is the size of Chiome Bioscience?

    Chiome Bioscience has 65 total employees.

  • What industry is Chiome Bioscience in?

    Chiome Bioscience’s primary industry is Drug Discovery.

  • Is Chiome Bioscience a private or public company?

    Chiome Bioscience is a Public company.

  • What is Chiome Bioscience’s stock symbol?

    The ticker symbol for Chiome Bioscience is 4583.

  • What is the current stock price of Chiome Bioscience?

    As of 13-Nov-2026 the stock price of Chiome Bioscience is $0.48.

  • What is the current market cap of Chiome Bioscience?

    The current market capitalization of Chiome Bioscience is $39.1M.

  • What is Chiome Bioscience’s current revenue?

    The trailing twelve month revenue for Chiome Bioscience is $3.98M.

  • What is Chiome Bioscience’s annual earnings per share (EPS)?

    Chiome Bioscience’s EPS for 12 months was -$0.08.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process